Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$8.02−0.60 (-6.96%)

Close on Nov 12, 2026Market cap $291.06MP/E –Yield –

Evommune ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Evommune's ebitda for the twelve months ending Sep 30, 2026 was -$121.29M. For fiscal 2025 it was -$80.47M.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$80.47M	–
FY2024	Dec 31, 2024	-$69.51M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$33.13M	–
Q2 FY2026	Jun 30, 2026	-$34.70M	–
Q1 FY2026	Mar 31, 2026	-$23.85M	–
Q4 FY2025	Dec 31, 2025	-$29.62M	–
Q3 FY2025	Sep 30, 2025	-$13.23M	–
Q2 FY2025	Jun 30, 2025	-$22.79M	–
Q1 FY2025	Mar 31, 2025	-$14.83M	–
Q4 FY2024	Dec 31, 2024	-$21.88M	–